Besides ABCC4, POLE3, POLE4, and the Fanconi anemia pathway genes FANCF and C17orf70 are top candidates that sensitize both wild-type and TDP1-KO cells to CPT treatment (Fig. 4a–c). This evidence concerns the gene TDP1 and Fanconi anemia.